Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03929731
Other study ID # R1597/96/2018
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 5, 2019
Est. completion date June 2025

Study information

Verified date April 2024
Source Singapore National Eye Centre
Contact Principal Investigator
Phone 63227460
Email gemmy.cheung.c.m@singhealth.com.sg
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To determine long-term outcomes, recurrence rates, and treatment needs in Polypoidal Choroidal Vasculopathy (PCV). Specifically, to describe the long-term outcomes, recurrence rates and treatment patterns PCV patients 5 years after first presentation. This study will also evaluate whether polyp closure within the first 12 months of therapy is associated with better long-term visual outcome and will also determine the risk of disease development in the fellow eye


Description:

The investigators will conduct a non-interventional, observational cohort study to assess the visual outcome of patients who have completed one of three recent randomized controlled trials in Polypoidal Choroidal Vasculopathy (PCV) EVERESTII, PLANET, PCV Treat and Extend (T&E) study. After completion of the randomized controlled trails (2 years for EVEREST II and PLANET; 1 year for T&E study), patients will be released from clinical trial protocol. At approximately 6 years (2019-2024), patients will be contacted by research coordinators and invited to attend a follow-up examination. Study Design: Non-interventional, observational, cohort study Clinical coordinators will contact patients of: - EVEREST II (2013-2015) - PLANET (2014-2015) - PCV T&E (2018-2019) at ~72 +/- 6 months after their initial baseline visits (2019-2024) Study Visits and Procedures Participants will only be expected to attend 1 evaluation clinic which will last approximately 3 hours Contact of prior trial participants Participants from prior randomized control trials (EVEREST II, PLANET and PCV T&E) will be contacted by phone and invited to attend 1 post-trial evaluation clinic. Historical Information A history will be elicited from the participant and extracted from available medical records. Data to be collected will include: age, gender, ethnicity and race, past medical history and medications being used, as well as ocular diseases, surgeries, and treatment. An assessment of visual related quality of life will be performed using the impact of visual impairment (IVI) questionnaire. Testing Procedures The following procedures will be performed (using the study technique and by delegated personnel) as part of usual care, it does not need to be repeated specifically for the study if it was performed within the defined time (within 14 days prior to visit). 1. Best-corrected Visual Acuity (BCVA) will be measured using the ETDRS VA protocol following manifest refraction. 2. Optical Coherence Tomography/ OCT Angiography: OCT and OCTA will be performed. Both standard and enhanced depth imaging scans will be performed. 3. Ocular examination on each eye including slit lamp, measurement of intra-ocular pressure, lens assessment, and dilated ophthalmoscopy. 4. Fundus Photography 5. Fundus fluorescein and Indocyanine Green angiography: FFA and ICGA will be performed. Disease characteristics of the study eye assessed by the investigator including: - Activity of PCV based on ICGA. - Presence of activity clinically as evidence by presence of hemorrhage, edema. - Presence of activity as evidence by intra retinal or sub retinal fluid on OCT. The clinical data from the exit of trial to this visit will be accessed from medical records both paper- based and electronic formats. All the data collected from this visit, data from the prior trial and the clinical course and treatment from the end of the trial to this visit will be anonymized and sent to the Singapore Eye Research Institution (SERI) for analysis. Only the principal investigator and study team at site and SERI will have access to the anonymized collected information.


Recruitment information / eligibility

Status Recruiting
Enrollment 72
Est. completion date June 2025
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Participants will have completed the previous PCV RCTs: EVEREST II, PLANET and PCV T&E studies - Are able to give consent for this follow up study Exclusion Criteria: - No exclusion criteria unless they do not meet the inclusion criteria

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Indocyanine Green Angiography
Intravenous injection of dye-indocyanine green

Locations

Country Name City State
Singapore National University Hospital Singapore
Singapore Singapore National Eye Centre Singapore
Singapore Tan Tock Seng Hospital Singapore

Sponsors (1)

Lead Sponsor Collaborator
Singapore National Eye Centre

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Long term prognostication Long term recurrence rates, correlated baseline characteristics and initial treatment strategies correlated to long term outcomes within 72 months
See also
  Status Clinical Trial Phase
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Active, not recruiting NCT01950741 - Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Phase 4
Completed NCT01469156 - Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy Phase 1/Phase 2
Recruiting NCT02597855 - Comparison of the Short-term Outcomes of Intravitreal Aflibercept Injection Between Two Subtypes of Polypoidal Choroidal Vasculopathy Using Indocyanine Green Angiography N/A
Completed NCT02495181 - Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy Phase 4
Active, not recruiting NCT02976194 - Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy Phase 4
Recruiting NCT01248117 - Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy Phase 1/Phase 2
Completed NCT01884597 - Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) Phase 1/Phase 2
Recruiting NCT04707027 - Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept N/A
Recruiting NCT02141308 - OCT in Rare Chorioretinal Diseases
Completed NCT01871376 - Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation Phase 4
Completed NCT00470977 - Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Phase 1/Phase 2
Recruiting NCT00383812 - Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy N/A
Completed NCT00837330 - Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy Phase 1/Phase 2
Completed NCT05229237 - Conbercept for Polypoidal Choroidal Vasculopathy(START Study)
Not yet recruiting NCT04380974 - Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy Phase 4
Recruiting NCT02815176 - Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers N/A
Active, not recruiting NCT00344617 - Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy Phase 3
Completed NCT01023295 - Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV) Phase 2
Completed NCT02821520 - Initial Versus Delayed PDT Combination With Conbercept in PCV Phase 4